Previously published proteomic studies analyzing the impact of AR antagonists on prostate cancer cell lines mainly focused on early, first-generation compounds and used two-dimensional gel electrophoresis, so that far fewer proteins were analyzed than in the present study [59,60]. This evidence concerns the gene AR and prostate carcinoma.